Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
    • Partnerships
    • In The News
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations

When a small molecule binds to the androgen receptor (AR), a conformational change can occur which impacts subsequent binding of co-regulator proteins and DNA. In order to accurately study this…

Read More
immun-ops2020 In Publications

Metastasis: Leveraging transcriptomics to identify potential therapeutics

Five-year survival rates for patients whose cancer has metastasized are dramatically lower than for those with localized disease. However, few therapeutic development efforts specifically focus on inhibiting the process of…

Read More
immun-ops2020 In Publications

Cachexia: Leveraging transcriptomics to identify potential therapeutics

Cachexia is a common cause of morbidity across multiple cancer types, yet remains largely under-studied especially in the realm of transcriptomics. An essential component of cancer cachexia is the induced…

Read More
immun-ops2020 In Publications

Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression

Objective: Investigate the role of S1R in the mechanism of action of pridopidine. Background: Sigma-1 receptor (S1R) is an ER chaperone protein involved in neuromodulation and neuroplasticity. Pridopidine is a…

Read More
immun-ops2020 In Publications

Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery

The tremendous expansion of data analytics and public and private big datasets presents an important opportunity for pre-clinical drug discovery and development. In the field of life sciences, the growth…

Read More
immun-ops2020 In Publications

A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets

Metastasis is a leading cause of cancer-associated deaths across several cancer types, yet the molecular details of its development have not been fully elucidated. Transcriptomic analysis can provide insight into…

Read More
immun-ops2020 In Publications

Cachexia mechanisms in cancer through the lens of transcriptomics

Introduction: Cachexia is a major clinical complication that affects up to 80% of patients with advanced cancer, and by some estimates is responsible for 20% of cancer deaths [1]. Despite…

Read More
immun-ops2020 In Publications

The international MAQC Society launches to enhance reproducibility of high-throughput technologies

Reproducibility is a fundamental hallmark of good science. The US Food and Drug Administration (FDA)-led Microarray and Sequencing Quality Control (MAQC/SEQC) consortia conducted three projects 1,2,3 to assess the reliability and…

Read More
immun-ops2020 In Publications

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…

Read More
immun-ops2020 In Publications

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…

Read More
Previous 1 … 4 5 6 7 8 … 10 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.